N811 Infliximab versus adalimumab: clinical and endoscopy response in ulcerative colitis patients. A prospective study

Abstract

Background: The anti-TNF agents are a new therapeutic strategy on Ulcerative Colitis (UC). Infliximab (IFX) and adalimumab (ADA) are effective in inducing and maintaining clinical remission and in reduction of hospitalizations and surgeries rates. The aim of this study was to compare the efficacy of IFX versus ADA in clinical response and endoscopic response in UC patients. Methods: A prospective and longitudinal study was carried out in UC patients. Patients were randomized to receive IFX or ADA and were evaluated at baseline and weeks 14, 30 and 54 of treatment. Mayo score ≤2 points was considered clinical remission and a decrease of ≥3 points was defined as clinical response. Endoscopic Mayo sub score of 1 or 0 was defined as endoscopic response. Statistical analysis: ANOVA and Tukey's multiple comparison test. Results: Thirty-one patients were included, the mean age was 42.06y (±15.70) and the mean duration of the disease was 4.84y (±4.00). Left colitis was found in 6 (19.35%) patients and pancolitis in 25 (80.65%) patients. Ten patients received ADA and 21 IFX, and no statistically significant difference between the groups in gender, mean age, disease duration and location, and Mayo score and Endoscopic Mayo sub score was found at baseline. Clinical response was observed in 6 (60%) patients from ADA group and in 12 (57.14%) patients from IFX group (p=1.0). Endoscopic response occurred in 3 (37.50%) patients in ADA group and in 9 (47.37%) patients from IFX group (p=0.70). The rate of hospitalization in the ADA group was 3 (30%) and 7 (33.33%) in IFX group (p=1.00). Conclusions: There were clinical and endoscopic response in patients with UC treated with anti-TNF agents. There was no difference between IFX and ADA group.